clinical trial recruitment

Clinical trials of two different exon-skipping compounds show encouraging results; Duchenne MD participants are being sought for new trials

posted on March 29, 2011 - 11:42am

sClinical trials that use compounds called antisense oligonucleotides to cause skipping of exon 51 of the dystrophin gene in individuals with Duchenne muscular dystrophy (DMD) are moving forward in the United States and elsewhere.
Exon skipping for DMD is a strategy that coaxes muscle fibers to ignore, or "skip," the genetic instructions for certain parts of the dystrophin gene so that functional...